NICE has released a statement today on the latest situation regarding its appraisal of the spinal muscular atrophy treatment Spinraza (also known as nusinersen).
NICE’s statement is as follows:
“Following the 2nd appraisal committee meeting for nusinersen on Tuesday 23 October, we advised registered stakeholders that NICE and Biogen were continuing to progress discussions and that we are not in a position to provide the outcome of the committee’s deliberations.
“We wish to reiterate to all stakeholders and the wider SMA community that these discussions remain ongoing. We recognise that this continuing uncertainty will be concerning for the community but please be assured that NICE are committed to swiftly progressing discussions with Biogen and NHS England and we will keep all those involved up to date with progress as soon as there is something to report.”
Alongside SMA UK and TreatSMA we are pressing NICE, NHS England and Biogen to be as flexible as possible in their negotiations so that a positive outcome can be reached at the earliest opportunity on access to Spinraza.
We will share further news and developments about the appraisal process when we receive them.